EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E -Mutant KRAS Wild-Type Metastatic Colorectal Cancer

Josep Tabernero iD, Eric Van Cutsem iD, Elena Garralda, David Tai, Filippo De Braud iD, Ravit Geva, Mark T J van Bussel, Katia Fiorella Dotti, Elena Elez iD, María J de Miguel, Kevin Litwiler, Danielle Murphy und 2 weitere

The Oncologist · 17.03.2023 · 28 (3) · 230-238

DOI: 10.1093/oncolo/oyad007 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Oncologist, online erschienen am 23.02.2023. Verfasst von Josep Tabernero und 13 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain. Hauptthemen laut MEDLINE: Hypercalcemia, Colorectal Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Khalifa Bin Zayed Al Nahyan Foundation, CG Johnson Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

WNT974 is a small molecule inhibitor of Wnt signaling that specifically inhibits porcupine O-acyltransferase. This phase Ib dose-­escalation study evaluated the maximum tolerated dose of WNT974 in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer with RNF43 mutations or RSPO fusions. Patients and Methods Patients received once-daily encorafenib and weekly cetuximab, in addition to once-daily WNT974, in sequential dosing cohorts. In the first cohort, patients received 10-mg WNT974 (COMBO10), which was reduced in subsequent cohorts to 7.5-mg (COMBO7.5) or 5-mg (COMBO5) after dose–limiting toxicities (DLTs) were observed. Primary endpoints were incidence of DLTs and exposure to WNT974 and encorafenib. Secondary endpoints were anti-tumor activity and safety.

Results

Twenty patients were enrolled (COMBO10, n = 4; COMBO7.5, n = 6; COMBO5, n = 10). DLTs were observed in 4 patients, including grade 3 hypercalcemia (COMBO10, n = 1; COMBO7.5, n = 1), grade 2 dysgeusia (COMBO10, n = 1), and lipase increased (COMBO10, n = 1). A high incidence of bone toxicities (n = 9) was reported, including rib fracture, spinal compression fracture, pathological fracture, foot fracture, hip fracture, and lumbar vertebral fracture. Serious adverse events were reported in 15 patients, most frequently bone fracture, hypercalcemia, and pleural effusion. The overall response rate was 10% and disease control rate 85%; most patients achieved stable disease as their best response.

Conclusion

Concerns surrounding the safety and lack of preliminary evidence of improved anti-tumor activity of WNT974 + encorafenib + cetuximab, compared with previous encorafenib + cetuximab data, ultimately led to study discontinuation. Phase II was not initiated.

Trial registration

ClinicalTrials.gov, NCT02278133

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercalcemiaColorectal NeoplasmsHumansCetuximabProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Antineoplastic Combined Chemotherapy ProtocolsMutationCarbamatesSulfonamidesPyrazinesPyridines

Stichwörter der Autor:innen

WNT974cetuximabcolorectal cancerencorafenibmetastatic

Substanzen

CetuximabProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)encorafenibCarbamatesSulfonamidesLGK974PyrazinesPyridinesKRAS protein, human

Autor:innen und Institutionen

  • Vall d'Hebron Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain.
  • University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.
  • START Madrid, Hospital Universitario HM Sanchinarro, Madrid, Spain.
  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.

ORCID-Profile: Josep Tabernero, Eric Van Cutsem, Filippo De Braud, Elena Elez

Förderung

  • NCI NIH HHS
  • Khalifa Bin Zayed Al Nahyan Foundation
  • CG Johnson Foundation
  • NIH
  • NCI

Zitieren

APA

Tabernero, J., Van Cutsem, E., Garralda, E., Tai, D., De Braud, F., Geva, R., van Bussel, M. T. J., Fiorella Dotti, K., Elez, E., de Miguel, M. J., Litwiler, K., Murphy, D., Edwards, M., & Morris, V. K. (2023). A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E -Mutant KRAS Wild-Type Metastatic Colorectal Cancer. The Oncologist, 28(3), 230-238. https://doi.org/10.1093/oncolo/oyad007

Vancouver

Tabernero J, Van Cutsem E, Garralda E, Tai D, De Braud F, Geva R, et al. A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E -Mutant KRAS Wild-Type Metastatic Colorectal Cancer. The Oncologist. 2023;28(3):230-238. doi:10.1093/oncolo/oyad007

BibTeX
@article{Tabernero2023,
  author = {Tabernero, Josep and Van Cutsem, Eric and Garralda, Elena and Tai, David and De Braud, Filippo and Geva, Ravit and van Bussel, Mark T J and Fiorella Dotti, Katia and Elez, Elena and de Miguel, María J and Litwiler, Kevin and Murphy, Danielle and Edwards, Michelle and Morris, Van Karlyle},
  title = {A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E -Mutant KRAS Wild-Type Metastatic Colorectal Cancer},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {3},
  pages = {230--238},
  doi = {10.1093/oncolo/oyad007}
}
Kostenlos starten →